Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Internal Probe Finds No Physical Evidence, Testimony in Ex-Sandoz Rep’s Residual Drug Resale Case
February 3, 2021
- Yoshindo Files Nesp Biosimilar in Japan
February 3, 2021
- Shonan iPark Begins Pilot Study to Build iPS Cell Donation Platform
February 3, 2021
- Hokkaido Univ., PuREC, Mochida Launch Joint Research on Novel Treatment for Spine-Related Diseases
February 3, 2021
- Nichi-Iko Closes Acquisition of Teva Takeda’s Generic Biz
February 2, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Astellas Returns Rights to Prostate Cancer Med to US Firm
February 2, 2021
- Sumitomo Dainippon to Invest Up to US$20 Million in US Venture Fund Focused on Digital Health
February 2, 2021
- Shuhei Sekiguchi to Become Janssen Japan Chief on March 1
February 2, 2021
- Sosei Ties Up with UK CRO to Identify Lead Compounds in Neurological Diseases
February 2, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Astellas Sees Growth of Evrenzo after 14-Day Prescription Limit Lifted: EVP
February 1, 2021
- FunPep Initiates Development of New IL-23 Antibody-Inducing Peptide
February 1, 2021
- Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
- Asahi Kasei Pharma Licenses Chronic Pain Drug AK1780 to Eli Lilly
February 1, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
- FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
- Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
January 29, 2021
- Fujifilm Toyama Chemical Files Radiopharmaceutical F-1614
January 29, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…